Related Experiment Videos
Recurrent herpes zoster myelitis treated with human interferon alpha: a case report
Acta Neurologica Scandinavica
|May 1, 1992
Summary
Recurrent herpes zoster myelitis is rare but was observed twice in a patient. Human interferon alpha (IFN-alpha) effectively treated the second episode, suggesting its role in managing VZV-related neurological complications.
Area of Science:
- Neurology
- Immunology
- Infectious Diseases
Background:
- Recurrent herpes zoster myelitis is an exceptionally rare neurological complication of varicella-zoster virus (VZV) reactivation.
- Understanding the immunopathogenesis of VZV-induced myelopathy is crucial for effective treatment strategies.
Observation:
- A 43-year-old woman experienced two distinct episodes of myelitis following herpes zoster (shingles) reactivation.
- The initial episode responded to methylprednisolone, but the second required human interferon alpha (IFN-alpha) for refractory sensory disturbances.
Findings:
- Elevated VZV antibodies were detected in serum but not cerebrospinal fluid during the second myelitis episode.
- IFN-alpha treatment correlated with increased natural killer cell activity, improved helper T-cell/suppressor T-cell ratio, and normalized kappa/lambda B-cell ratios.
- These immunological changes suggest a role for delayed-type hypersensitivity in VZV myelopathy and therapeutic immunosuppression by IFN-alpha.
Implications:
- This case highlights the potential for recurrent VZV myelitis and the limitations of standard immunosuppression in severe cases.
- IFN-alpha demonstrates therapeutic potential for refractory VZV-related myelopathy by modulating specific immune responses.
- Further research into the immunological mechanisms underlying VZV myelitis is warranted to optimize patient outcomes.